Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
In the latest session, Supernus Pharmaceuticals Inc (NASDAQ: SUPN) closed at $51.71 up 0.41% from its previous closing price of $51.5. In other words, the price has increased by $0.41 from its previous closing price. On the day, 1.32 million shares were traded. SUPN stock price reached its highest trading level at $52.2807 during the session, while it also had its lowest trading level at $51.25.
Ratios:
For a deeper understanding of Supernus Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 41.91. For the most recent quarter (mrq), Quick Ratio is recorded 1.56 and its Current Ratio is at 1.80. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On July 30, 2025, Cantor Fitzgerald Upgraded its rating to Overweight which previously was Neutral but kept the price unchanged to $42. Cantor Fitzgerald Downgraded its Overweight to Neutral on February 19, 2025, whereas the target price for the stock was revised from $57 to $36.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 19 ’25 when Mottola Frank sold 20,000 shares for $50.41 per share. The transaction valued at 1,008,150 led to the insider holds 15,496 shares of the business.
FRANK MOTTOLA bought 20,000 shares of SUPN for $985,600 on Dec 19 ’25. On Dec 18 ’25, another insider, Bhatt Padmanabh P., who serves as the Sr. VP of IP, CSO of the company, sold 710 shares for $44.44 each. As a result, the insider received 31,552 and left with 14,508 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SUPN now has a Market Capitalization of 2965017856 and an Enterprise Value of 2726069760. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.88. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.35 while its Price-to-Book (P/B) ratio in mrq is 2.81. Its current Enterprise Value per Revenue stands at 4.0 whereas that against EBITDA is 22.92.
Stock Price History:
The Beta on a monthly basis for SUPN is 0.68, which has changed by 0.4195149 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, SUPN has reached a high of $57.65, while it has fallen to a 52-week low of $29.16. The 50-Day Moving Average of the stock is 6.75%, while the 200-Day Moving Average is calculated to be 30.84%.
Shares Statistics:
For the past three months, SUPN has traded an average of 836.44K shares per day and 692800 over the past ten days. A total of 57.12M shares are outstanding, with a floating share count of 54.43M. Insiders hold about 5.07% of the company’s shares, while institutions hold 101.45% stake in the company. Shares short for SUPN as of 1764288000 were 4994703 with a Short Ratio of 5.97, compared to 1761868800 on 4870017. Therefore, it implies a Short% of Shares Outstanding of 4994703 and a Short% of Float of 12.29.
Earnings Estimates
Current recommendations for the stock of the company come from 3.0 analysts. The consensus estimate for the next quarter is $0.44, with high estimates of $0.47 and low estimates of $0.42.
Analysts are recommending an EPS of between $5.95 and $2.64 for the fiscal current year, implying an average EPS of $3.81. EPS for the following year is $4.25, with 3.0 analysts recommending between $6.04 and $3.25.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $195.64M this quarter.It ranges from a high estimate of $202.7M to a low estimate of $184.8M. As of. The current estimate, Supernus Pharmaceuticals Inc’s year-ago sales were $174.16MFor the next quarter, 6 analysts are estimating revenue of $192.34M. There is a high estimate of $203.7M for the next quarter, whereas the lowest estimate is $182.5M.
A total of 6 analysts have provided revenue estimates for SUPN’s current fiscal year. The highest revenue estimate was $710M, while the lowest revenue estimate was $692.2M, resulting in an average revenue estimate of $703M. In the same quarter a year ago, actual revenue was $661.82MBased on 6 analysts’ estimates, the company’s revenue will be $867.27M in the next fiscal year. The high estimate is $902.5M and the low estimate is $824.1M.
